• Moberg Derma AB, of Stockholm, Sweden, said it received the final results from a Phase II study of MOB-015 in patients with onychomycosis and, because the clinical efficacy was unsatisfactory, said it decided to initiate a new study with an improved formulation. The new trial, set to enroll 35 patients, will start in December.
Suite: 1100 | Atlanta, Georgia 30346, USA
Outside of the US
In the U.S. and Canada: +1-800-336-4474
Outside the U.S.: +44-203-684-1796
Hours: Monday - Friday, 8:00am - 6:00 pm EST
Sign up for Highlights FREE e-mail newsletter